However, whether inflammation is the cause or the consequence of atrial fibrillation and which specific inflammatory mediators may increase the atria's susceptibility to fibrillation remain elusive. Here we provide experimental and clinical evidence for the mechanistic involvement of myeloperoxidase (MPO), a heme enzyme abundantly expressed by neutrophils, in the pathophysiology of atrial fibrillation. MPO-deficient mice pretreated with angiotensin II (AngII) to provoke leukocyte activation showed lower atrial tissue abundance of the MPO product 3-chlorotyrosine, reduced activity of matrix metalloproteinases and blunted atrial fibrosis as compared to wild-type mice. Upon right atrial electrophysiological stimulation, MPO-deficient mice were protected from atrial fibrillation, which was reversed when MPO was restored. Humans with atrial fibrillation had higher plasma concentrations of MPO and a larger MPO burden in right atrial tissue as compared to individuals devoid of atrial fibrillation. In the atria, MPO colocalized with markedly increased formation of 3-chlorotyrosine. Our data demonstrate that MPO is a crucial prerequisite for structural remodeling of the myocardium, leading to an increased vulnerability to atrial fibrillation.
Atrial fibrillation remains the most common arrhythmia in humans and stands out as a major contributor to morbidity and mortality [2] [3] [4] . Despite recent advances in pharmacological and invasive strategies to treat atrial fibrillation, the underlying pathophysiology remains incompletely understood. Past attempts to elucidate the pathophysio logy of atrial fibrillation mainly focused on the electrical substrate, with an increasing number of studies now suggesting that atrial fibrillation shows the pathophysiological characteristics of an inflam matory disease 1 . Clinical investigations have reported multiple asso ciations between vulnerability to atrial fibrillation and circulating levels of cytokines, Creactive protein, complement [5] [6] [7] and, in parti cular, the activation state of leukocytes [8] [9] [10] . Whether this inflamma tory phenotype represents an epiphenomenon in atrial fibrillation or is causally linked to the initiation and progression of atrial fibrillation remains unclear.
A key mechanistic link by which inflammation may contribute to atrial fibrillation seems to be atrial fibrosis. Increased deposition and turnover of matrix proteins within the atria is accelerated in atrial myocytes after challenge with cytokines, Creactive protein and complement 1 . Key effectors of extracellular matrix (ECM) turnover are matrix metalloproteinases (MMPs), enzymes that have been strongly linked to ECM remodeling in atrial fibrillation 11 . Notably, the activity of MMPs is regulated by redox reactions. Recent reports suggest that the leukocytederived heme enzyme MPO, by generating hypochlorous acid (HOCl), is a crucial regulatory switch modulating MMP activity 12, 13 . Given the ability of MPO to leave the circulation by avidly binding to and transcytosing endothelial cells 14 , we investi gated the role of MPO in the initiation and perpetuation of atrial fibrillation and its contribution to structural changes in the heart, including atrial fibrosis.
To elucidate the role of MPO in structural remodeling of the atria, we performed histological and liquid chromatography-mass spectro metry (LCMS)based studies of the atria from MPOdeficient mice (Mpo −/− ) and C57BL/6 wildtype (WT) mice. In WT mice, a 2week subcutaneous infusion of AngII, an effector of atrial remodeling and fibrosis [15] [16] [17] [18] , substantially increased circulating MPO plasma concentrations and elevated myocardial deposition of MPO (Fig. 1a,b) . Picrosirius red staining revealed marked attenuation of atrial fibrosis in AngII-treated Mpo −/− mice compared to AngIItreated WT mice (Fig. 1c,d ). In support of the concept that atrial fibrosis depends on MPO, administration of recombinant MPO (intravenously via osmotic pumps) to Mpo −/− mice led to the develop ment of a similar degree of atrial fibrosis as that observed for AngII or MPOinfused WT mice. This finding reveals that atrial fibrosis developed independently of AngII administration indicating that MPO, once present in the tissue, does not require AngII as a cofac tor ( Supplementary Fig. 1a,b) . To further characterize the molecu lar basis of MPOdependent atrial remodeling, we determined atrial MMP2 and MMP9 enzymatic activities. These activities were both profoundly reduced in AngII-treated Mpo −/− mice, as assessed by zymography and by immunoblot analysis of MMP9 (Fig. 1e,f) . Given that MMPs are known to be activated by HOCl, we determined atrial tissue amounts of 3chlorotyrosine, a specific footprint of MPO dependent HOCl formation. Mass spectrometry-based quantitative analysis and immunohistochemical studies both showed markedly less formation of 3chlorotyrosine in Mpo −/− mice after AngII treatment (Fig. 1g,h) , indicating lower HOCl bioavailability in these mice.
To test whether MPOdependent structural remodeling also trans lated into increased electrical instability and thus higher vulnerability for the development of atrial fibrillation, we subjected Mpo −/− and WT mice to electrophysiological investigation in vivo 19 (Fig. 2) . Upon right atrial electrophysiological stimulation, WT mice challenged with AngII showed a higher susceptibility to atrial fibrillation compared to vehicletreated WT mice, with a higher number and duration of atrial fibrillation episodes, as well as an increased probability of atrial fibrillation induction (Fig. 2a,c,e) . In sharp contrast, AngII treatment did not affect the inducibility of atrial fibrillation in Mpo −/− mice, indicating an almost complete protection from atrial fibrillation in Mpo −/− mice (Fig. 2a,c,e) . However, continuous intravenous supple mentation of recombinant MPO via minipumps reestablished the vulnerability to atrial fibrillation in Mpo −/− mice ( Fig. 2a-f) ; this effect was dose dependent and occurred in the absence of AngII administration (Supplementary Fig. 2 ). These results indicate that MPO, upon intravenous infusion and thus independently of leuko cytes, and independently of AngII, can promote electrical instability in the atria. This suggests that MPO not only is a marker of leukocyte activation but also is mechanistically involved in the induction of atrial fibrillation, whereas AngII seems to unfold its proarrhythmic properties in large part by activation of leukocytes.
To further evaluate whether MPOdependent atrial fibrosis increases atrial conduction inhomogeneity, an electrophysiological hallmark of atrial fibrillation 20 , we performed epicardial activation mapping in Langendorffperfused hearts from WT and Mpo −/− mice 21 . Atria from AngIItreated Mpo −/− mice, in sharp contrast to atria from AngII challenged WT mice, showed no retardation in conduction velocity ( Fig. 3a-f) ; this finding complements the histological observations of attenuated atrial fibrosis in AngIItreated Mpo −/− mice. Accordingly, in vivo surface electrocardiogram tracings showed a significant pro longation of P wave duration in WT mice upon AngII treatment (P < 0.001, Supplementary electrophysiology of atrial cells ( Supplementary Fig. 3a-d ). In addition, plasma potassium concentrations, a key covariate for the electrical stability of the atria, were similar across the four treatment groups (data not shown).
Given the welldocumented effects of AngII on blood pressure, the cytokinelike, leukocyteactivating properties of AngII 22 and the estab lished nitric oxide-consuming properties of MPO 23, 24 , we assessed hemodynamics in AngIItreated WT and MPOdeficient mice by in vivo radiotelemetric blood pressure measurements. Whereas base line blood pressure was not different between groups ( Supplementary  Fig. 4a ), the blood pressure-elevating effect of AngII in WT mice was blunted in Mpo −/− mice ( Supplementary Fig. 4b ). Conversely, blood pressure in Mpo −/− mice reconstituted with MPO in the absence of AngII remained unaltered as compared to vehicletreated mice ( Supplementary Fig. 5a ,b), indicating that MPOdependent effects on vascular tone and on structural atrial remodeling are differentially regulated. Echocardiographic studies revealed no changes in atrial diameters across groups (Supplementary Fig. 4c ). Taken together, these observations reinforce the idea that electrical instability evoked by MPO does not simply reflect changes in systemic vasomotion and atrial dimensions but is functionally linked to structural transformation within atrial tissue.
To evaluate MPOdependent effects on atrial remodeling in humans, we tested whether the incidence of atrial fibrillation in individuals implanted with pacemakers (n = 42) for a period of 114 ± 73 d (Supplementary Table 2 ) correlated with MPO plasma concentrations. Studying individuals who all were carriers of a newgeneration dualchamber pacemaker allowed for continuous atrial sensing over the entire followup period for the detection of atrial fibrillation. Twentyfour individu als showed atrial fibrillation (atrial fibrilla tion burden defined as the percentage of time during which the atrial rate of depolarization exceeded 200 per min: 45.2% ± 39.9%, equaling 871 ± 1,541 h of atrial fibrillation). The indi viduals with atrial fibrillation showed signifi cantly higher MPO plasma concentrations than those without atrial fibrillation (503.1 pmol l −1 (interquartile range: 404.6-880.7 pmol l −1 ) versus 437.8 pmol l −1 (interquartile range 348.9-488.0 pmol l −1 ; P = 0.025)), which correlated with the atrial fibril lation burden (Spearman's rho: 0.5; P = 0.002). Circulating concentra tions of elastase, an enzyme stored in the same neutrophil granules as MPO, were also significantly elevated in individuals with atrial fibrillation (50.5 ± 23.9 ng ml −1 versus 38.3 ± 12.4 ng ml −1 ; P = 0.039), and also correlated with the atrial fibrillation burden (r = 0.5; P = 0.004), under scoring the concept that increased MPO concentrations are a reflection of leukocyte activation and degranulation.
To test whether MPO is locally sequestered within the atria, we measured MPO concentrations and performed immunohistochemi cal studies in specimens derived from right atrial appendages of a cohort of individuals undergoing coronary bypass surgery (n = 27, Supplementary Table 3) . Individuals with concomitant atrial fibrilla tion showed substantially higher atrial MPO deposition (Fig. 4a) and enhanced tissue 3chlorotyrosine content (Fig. 4b) , which colocalized with MPO, as evidenced by immunohistochemistry (Fig. 4c) . These findings underscore the role of MPO as a mediator of the observed posttranslational protein modification 3chlorotyrosine.
Our current work suggests that MPO is linked to the pathophysio logy of atrial fibrillation. We found that the availability of MPO was increased systemically and locally in humans and mice with atrial fibrillation; MPO administration to mice led to structural changes, namely atrial fibrosis, known to be associated with the development of atrial fibrillation; genetic deficiency of MPO in mice profoundly decreased their vulnerability to atrial fibrillation; and reconstitution of MPO in these mice reestablished their vulnerability to atrial fibril lation in an AngII-independent fashion.
Atrial fibrosis is considered a key prerequisite for the initiation and propagation of atrial fibrillation [25] [26] [27] and serves as a substrate for atrial fibrillation 20 . In considering subcellular mediators linking structural changes in the atria and the susceptibility for atrial fibrillation, AngII stands out as having a central role. AngII, generated either systemically or locally in the atria, propagates atrial dilatation, fibrosis and, ulti mately, atrial fibrillation 17 . Our data extend the understanding of the contributory role of AngII in atrial fibrillation by revealing that AngII also elicits profibrotic and proarrhythmic properties independent of its direct effects on cardiac myocytes. Mpo −/− mice showed markedly reduced atrial fibrosis and were almost completely protected from the increased vulnerability to atrial fibrillation caused by AngII admin istration; both of these effects were dosedependently reversed upon restitution of MPO. Thus, MPO acts as a major downstream mediator of atrial fibrosis and atrial arrhythmogeneity.
In search of the molecular mechanisms underlying MPOdependent atrial fibrosis, we focused on atrial MMP activity. Increased activity of MMPs has been firmly linked to elevated atrial ECM turnover, fibrosis and atrial fibrillation 11 . MPO regulates MMP activity via post translational modifications mediated by generation of HOCl in a concentrationdependent manner 12, 13 . Here we showed that the abundance of 3chlorotyrosine, a posttranslational modification of proteins by the MPOgenerated oxidant HOCl 28 , was increased within the atrial tissue of WT mice treated with AngII compared to vehicle treated WT mice. The reduction in atrial tissue 3chlorotyrosine content in Mpo −/− mice was accompanied by substantially reduced endogenous MMP activity in atria from these mice, consistent with the idea that MPOdependent regulation of MMP activity is a key contributor to increased ECM turnover and atrial fibrosis.
The electrophysiological data obtained from vehicle, AngII and MPOtreated Mpo −/− mice complement these structural findings and identify a specific inflammatory mediator crucially linked to atrial fibrillation. These findings support the notion that MPO binding to the atria, protein oxidation and atrial fibrosis are required for the development of atrial fibrillation, a conclusion that was also supported by study of atrial specimens from humans with atrial fibrillation.
Certainly, other MPOcatalyzed oxidation reactions linked to increased cardiomyocyte apoptosis or inactivation of redoxsensitive enzyme systems such as myofibrillar creatine kinase 29 may also contribute to protection from atrial fibrillation in MPOdeficient mice. Furthermore, MPOdependent oxidants have been linked to inhibition of inhibitors of protease cascades such as α1antitrypsin 30 and tissue inhibitors of matrix metalloproteinases 31 . In addition, elevated arterial blood pressure in AngIItreated, MPOcompetent mice may also have promoted atrial fibrosis. However, the fact that MPO supplementation alone did not affect blood pressure indicates that the observed structural effects mediated by MPO do not depend on increased afterload.
Taken together, the evidence provided here-documenting atrial accumulation of MPO accompanied by augmented fibrosis in mice and humans with atrial fibrillation-suggests that MPO is intimately involved in the pathophysiology of atrial fibrillation. Given that cur rent pharmacological strategies to treat atrial fibrillation are, for the most part, of limited clinical efficacy and directed mainly at ion channels, MPO may serve as a potential new target of treatment in this disease.
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Angiotensin II and myeloperoxidase treatment of mice. We treated male C57BL/6J (WT) and MPO tm1lus mice (Mpo −/− , Jackson Laboratory) on a C57BL/6 back ground, aged 12-15 weeks, via ALZET osmotic pumps with AngII (1.5 ng per g body weight per min, Sigma) or saline (vehicle) for 14 d before electrophysiological inves tigation. We treated another cohort of WT and Mpo −/− mice via ALZET osmotic pumps with a connected jugular catheter with recombinant MPO (3174MP250, R&D Systems, 5.0, 12.5 and 50 pg per g body weight per min, which we calculated to generate physiological plasma concentrations of MPO ranging between 100 and 1100 pM) or recombinant human serum albumin (Sigma) for 7 d in combination with either AngII or saline before electrophysiological investigation. Mouse experi ments conformed with the Guide for the Care and Use of Laboratory Animals pub lished by the US National Institutes of Health and were approved by the Institutional Review Boards of the University of Hamburg and the University of Bonn.
Electrophysiological investigation. We examined mice electrophysio logically by a single catheter technique 19, 32 . We analyzed standard electro cardiogram parameters obtained by a sixlead surface electrocardiogram. Electrophysiological investigation included transvenous atrial and ventricular recording and stimulation 21 . For induction of atrial fibrillation, we performed atrial and ventricular burst and programmed atrial stimulations. We defined atrial fibrillation as rapid and fragmented atrial electrograms with irregular atrioventricularnodal conduction for >1 s. We classified atrial fibrillation epi sodes persisting longer than 1 min as sustained atrial fibrillation. We analyzed the number, duration and probability of inducible atrial fibrillation episodes.
Epicardial mapping of Langendorff-perfused hearts. We determined spon taneous and stimulated myocardial conduction velocities and characteristics of Langendorffperfused hearts by epicardial activation mapping with a 128electrode array 21 .
Ex vivo electrophysiology studies. We isolated atrial myocytes enzymatically from WT and Mpo −/− mice and recorded action potentials by the ruptured patch wholecell patchclamp technique 33 .
Assessment of myeloperoxidase content in human and mouse plasma and atrial tissue. We determined MPO concentrations by ELISA according to the manufacturer's instructions (human: CardioMPO kit, PrognostiX; mouse: HK210 kit, Hycult Biotechnology).
Detection of myeloperoxidase, 3-chlorotyrosine and matrix metalloproteinase-9. We incubated sections of human right atrial appendages and mouse atrial tissue with antibodies to MPO (475915, Calbiochem) and to chloro tyrosine (HP5002, Hycult Biotechnology). We assessed the proteinbound 3chlorotyrosine content of mouse and human hearts by stable isotope dilution liquid chromatography with online tandem mass spectrometry on a triple quadrupole mass spectrometer (ABI 3000 with redesigned source by Ionics) interfaced to an Aria LX Series HPLC (Cohesive Technologies) 34 . In brief, before tissue homogenization and acid hydrolysis with methane sulfonic acid, we added synthetic [ 13 C 6 ]3chlorotyrosine to samples as an internal standard for quantification of 3chlorotyrosine. Simultaneous monitoring for the potential formation of artifactual 3chlorotyrosine (detected as [ 13 C 9 , 15 N] isotopomer) during sample preparation showed no detectable intrapreparative chlorination under the assay conditions employed. We detected pro-MMP9 and MMP9 by western blotting with a specific antibody (AF909, R&D Systems).
Histological assessment of fibrosis in mouse atria. We used the picrosirius polarization method for quantitative evaluation of fibrosis 35 . Quantitative analysis was performed by two independent pathologists blinded to the identity of the treatment groups.
Gelatin zymography. We performed zymography to measure MMP2 and MMP9 activities as described previously 11 .
Radiotelemetric blood pressure measurements. We performed blood pre ssure measurements as described previously 36 . In brief, we inserted the tip of the telemetry device (TA11PAC10; Data Sciences International) into the carotid lumen. After 10 d, data acquisition started for 1 min every 5 min for 3 d. Thereafter, we started AngII, MPO or vehicle treatment. We recorded blood pressure and heart rate for one week in MPOtreated mice and 2 weeks in AngIItreated mice starting 3 d after minipump implantation.
Mouse echocardiographic studies. We determined maximal left atrial diameters in a modified parasternal longaxis view with a Vevo 770 microimaging system equipped with a 30MHz center frequency singleelement transducer.
Human study outline. Human studies, performed in accordance with the Declaration of Helsinki, were approved by the Board of Physicians Ethics Committee Hamburg, and we obtained written informed consent. We included 42 individuals with an already implanted newergeneration, dualchamber pacemaker in the study, which allowed for continuous monitoring of atrial rhythm. Exclusion criteria were acute coronary syndrome within 1 month before study entry, decompensated heart failure, acute or chronic infec tions, malignancies, autoimmune disorders, renal failure and severe valvular dysfunction. At baseline, we collected venous blood samples and carried out transthoracic echocardiography to assess ejection fraction according to Simpson's rule, functional status of the heart valves and left atrial diameter 37 . We performed pacemaker interrogation to obtain the intervention rate, the time interval since the last interrogation and the atrial fibrillation burden at baseline and after 3 months of the followup period. We defined the atrial fibrillation burden as the percentage of time during which the atrial rate of depolarization exceeded 200 per min. We defined the presence of atrial fibrillation as an atrial fibrillation burden greater than 0% according to the memory readout of the pacemaker. We also obtained right atrial appendages from 27 individuals undergoing elective coronary artery bypass surgery (ten individuals with persistent atrial fibrillation and 17 without atrial fibrilla tion). We determined plasma and atrial concentrations of MPO (CardioMPO, PrognostiX) and plasma concentrations of elastase (RE70731, IBL) by ELISA according to the manufacturer's recommendations. We assessed amounts of atrial 3chlorotyrosine by LCMS as stated above.
Statistical analyses.
The aim of the human study was to detect a minimal dif ference of 15% in MPO plasma concentrations (logarithmized because of an assumed nonnormal distribution) between the two groups with a twosided α of 0.05 and a power (1 -β) of 0.80. Sample size calculation based on previous trials gave a formal sample size of n = 17. Categorical data are presented as frequencies, and we compared percentages and by χ 2 test. We tested continu ous variables for normal distribution using the KolmogorovSmirnov test. Normallydistributed variables are presented as mean ± s.d.; for nonnormally distributed data, the median and interquartile range is given. To test for differ ences between groups, we used Student's t test for normally distributed data and the MannWhitney U test for nonnormally distributed data. In the case of multiple groups, we used oneway ANOVA with Bonferroni's post hoc test or the KruskalWallis test with the MannWhitney U post hoc test. We assessed correlations between parameters with Spearman's correlation according to distribution of data. We considered a P value <0.05 as statistically significant. We carried out all statistical analyses with SPSS Version 15.0 (SPSS).
